methyl N-methyl-caproylamido-biotin

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 生物素及其衍生物
• 英文名称: methyl N-methyl-caproylamido-biotin
• 英文别名: 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;N,2-dimethylhexanamide
• 化学式: C₈H₁₇NO*C₁₀H₁₆N₂O₃S
• 分子量: 387.544
• InChiKey: IMNKBTKEIQTHHP-UFLZEWODSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.36
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  133
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  methyl 6-(methylamino)hexanoate hydrochloride 、 (+)生物素-N-琥珀酰亚胺基酯 生成 methyl N-methyl-caproylamido-biotin
  参考文献：
  名称：

  THREE-STEP PRETARGETING METHODS AND COMPOUNDS

  摘要：

  涉及预定位递送诊断和治疗药物的方法、化合物、组合物和试剂盒已被披露。具体而言，描述了三步预定位方法。

  公开号：

  US20020015705A1

文献信息

• Small molecular weight ligand-hexose containing clearing agents
  申请人：NeoRx Corporation

  公开号：US06075010A1

  公开（公告）日：2000-06-13

  Small molecule weight clearing agents containing ligands such as biotin or biotin analogs and hexose residue, in particular galactose or N-acetyl galactosamine residues are taught. These clearing agents effectively clear anti-ligand containing conjugates in vivo via hepatocyte receptor mediated clearance mechanisms.

  含有生物素或生物素类似物和六碳糖残基，特别是半乳糖或N-乙酰半乳糖氨基残基的小分子重量清除剂被教授。这些清除剂通过肝细胞受体介导的清除机制有效地清除体内含有抗配体的结合物。
• Pretargeting methods and compounds
  申请人：NeoRx Corporation

  公开号：US05541287A1

  公开（公告）日：1996-07-30

  Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.

  涉及预定位传递诊断和治疗药剂的方法、化合物、组合物和试剂盒已被披露。具体来说，描述了生物素的放射金属标记方法，以及相关化合物。还讨论了在预定位方法中有用的制品。
• Three-step pretargeting methods using improved biotin-active agent
  申请人：Neorx Corporation

  公开号：US05578287A1

  公开（公告）日：1996-11-26

  Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, three-step pretargeting methods are described.

  涉及预定位递送诊断和治疗药物的方法、化合物、组合物和试剂盒已被披露。具体来说，描述了三步预定位方法。
• Biotinidase-resistant biotin-DOTA conjugates
  申请人：NeoRx Corporation

  公开号：US05608060A1

  公开（公告）日：1997-03-04

  Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.

  提供了抗生物素酶抗性的生物素-DOTA共轭物，并提供了在诊断和治疗前靶向方法中使用它们的方法。这些共轭物在癌症的诊断和治疗中非常有用。
• Two-step pretargeting methods using improved biotin-active agent
  申请人：NeoRx Corporation

  公开号：US05630996A1

  公开（公告）日：1997-05-20

  Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

  涉及预定位传递诊断和治疗药物的方法、化合物、组合物和试剂盒被披露。具体来说，描述了生物素的放射金属标记方法、生物素的改进放射卤素化方法以及相关化合物。此外，还讨论了清除剂、抗配体靶向基团共轭物、靶细胞保留增强基团和其他方法。